Cooper Companies (NASDAQ:COO) Announces Quarterly Earnings Results

Posted by Teresa Graham on Mar 7th, 2026

Cooper Companies (NASDAQ:COO – Get Free Report) announced its quarterly earnings results on Thursday. The medical device company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.07, FiscalAI reports. Cooper Companies had a net margin of 9.67% and a return on equity of 10.36%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same period last year, the firm posted $0.92 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. Cooper Companies updated its Q2 2026 guidance to 4.580-4.660 EPS.

Here are the key takeaways from Cooper Companies’ conference call:

Cooper reported a strong quarter with non‑GAAP EPS up 20% to $1.10, $159M of free cash flow, and raised full‑year guidance to $4.58–$4.66 EPS and $600–$625M free cash flow.
CooperVision continued product‑led share gains (18th consecutive year), driven by the MyDay premium portfolio and MiSight (MiSight sales up 23%), plus multiple new branded and private‑label contract wins and global rollouts.
Asia‑Pacific disappointed, led by softness in Japan from legacy hydrogel products; management expects APAC to remain down in Q2 and recover by fiscal Q3, creating near‑term revenue risk.
Organizational changes, IT/AI implementations and cost synergies lifted margins (gross margin 68.1%, operating income +13.9%) and are funding reinvestment in sales/marketing, buybacks ($92M repurchased) and debt reduction.
CooperSurgical showed early fertility market recovery and solid surgical product trends, but exposure to the Middle East (~2% of sales) and uncertain timing of equipment installations leave near‑term visibility mixed.

Cooper Companies Stock Down 4.6%

Shares of NASDAQ COO opened at $76.55 on Friday. The stock has a market capitalization of $14.94 billion, a P/E ratio of 37.90, a PEG ratio of 2.29 and a beta of 1.02. The stock’s fifty day moving average is $82.11 and its 200 day moving average is $75.97. Cooper Companies has a 52 week low of $61.78 and a 52 week high of $89.83. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89.

Insider Activity

In other Cooper Companies news, CEO Albert G. White III purchased 10,000 shares of the stock in a transaction dated Tuesday, December 16th. The stock was bought at an average price of $80.80 per share, with a total value of $808,000.00. Following the acquisition, the chief executive officer owned 236,151 shares of the company’s stock, valued at approximately $19,081,000.80. This represents a 4.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Maria Rivas acquired 1,000 shares of Cooper Companies stock in a transaction that occurred on Thursday, December 18th. The stock was acquired at an average cost of $82.13 per share, for a total transaction of $82,130.00. Following the completion of the purchase, the director directly owned 11,141 shares of the company’s stock, valued at $915,010.33. This represents a 9.86% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders acquired 16,014 shares of company stock valued at $1,304,416. Company insiders own 2.08% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of COO. State Street Corp increased its position in Cooper Companies by 2.4% during the 4th quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock worth $720,736,000 after purchasing an additional 207,195 shares in the last quarter. Wellington Management Group LLP raised its position in Cooper Companies by 332.9% during the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after purchasing an additional 4,756,178 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Cooper Companies by 58.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock worth $494,123,000 after acquiring an additional 2,231,568 shares during the last quarter. Sustainable Growth Advisers LP raised its holdings in Cooper Companies by 22.1% during the 3rd quarter. Sustainable Growth Advisers LP now owns 4,132,535 shares of the medical device company’s stock worth $283,327,000 after purchasing an additional 747,476 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in Cooper Companies by 98.8% during the second quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock worth $241,120,000 after buying an additional 1,683,561 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on COO. Barclays boosted their target price on Cooper Companies from $98.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday. Robert W. Baird raised their target price on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Rothschild & Co Redburn downgraded Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 price target for the company. in a research note on Wednesday. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings raised Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.79.

Get Our Latest Stock Analysis on COO

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free‑cash‑flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer‑term upside. Read More.
Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell‑side analysts. This creates potential catalyst if buyers follow through. Read More.
Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above‑average financial growth and attractive style scores, which may keep the stock on growth‑oriented portfolios but don’t guarantee near‑term momentum. Read More.
Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact‑lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in‑line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near‑term recovery in core vision that can limit upside until clearer top‑line improvement is visible. Read More.

About Cooper Companies

(Get Free Report)

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.